Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $8.95
Previous CloseN/A
Volume480.81K
Average Volume (3M)1.96M
Market Cap
$1.25B
Enterprise Value$736.28M
Total Cash (Recent Filing)$47.92M
Total Debt (Recent Filing)$89.39M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Apr 30, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding148,582,200
10 Day Avg. Volume2,148,138
30 Day Avg. Volume1,962,137
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.04
Price to Cash Flow (P/CF)-11.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
$9.57Price Target Upside10.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Adaptive Biotechnologies News
PremiumCompany Announcements
Adaptive Biotechnologies Shines in 2024 Earnings Call---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADPT delivers solid Q4 results, sets what looks like a more achievable bar than in prior years, and raises the price target to $10.
Market PositionAnalyst is upgrading ADPT to Buy from Neutral to reflect their solid position in the attractive MRD market with compelling initiatives to drive increasing penetration while limiting cash burn in their Immune Medicine business.
Bears Say
Operational ConcernsCaution around speed of trial completion and delays due to political risk on FDA disruption of trial timing under new leadership.
Revenue DeclineImmune Medicine revenue decreased by 51% year over year, with a significant decline in Genentech amortization and lower pharma and academic services revenue.
---
Ownership Overview
4.18% Insiders
13.84% Mutual Funds
0.26% Other Institutional Investors
64.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $2.28 and its highest was $8.95 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $1.25B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Apr 30, 2025 which is in 36 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Feb 11, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.256 by $0.026.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.29.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 148,582,200 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.256. Following the earnings report the stock price went down -3.205%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
---
Adaptive Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.57 (10.51% Upside)
$9.57 (10.51% Upside)
Blogger Sentiment
Bullish
ADPT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $733.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.25%
12-Months-Change
Fundamentals
Return on Equity
-62.41%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
---
ADPT Company Deck
---
ADPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive view of Adaptive Biotechnologies' performance for 2024, highlighting significant growth in MRD revenue, improvements in operational efficiency, and a strong cash position. These positive developments were slightly offset by challenges in the immune medicine segment and a conservative outlook for MRD Pharma Services.Read More>---
ADPT Stock 12 Month Forecast
Average Price Target
$9.57
▲(10.51% Upside)
Technical Analysis
Illumina
―
Crispr Therapeutics AG
―
Guardant Health
―
10x Genomics
―
Beam Therapeutics
―
Best Analysts Covering ADPT
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+22.18%
reiterated a buy rating last month
Copying David Westenberg's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +22.18% per trade.
---